Jim Cramer - Mad Money The Beauty Health Company SKIN-Q BUY Jun 25, 2021

He's shilling pitching this on the show. SKIN's product is a fast, affordable and non-invasive skin treatment that clean and hydrates your skin for everyone--men, women, young and old. Company had 52% revenue compounded growth, pre-Covid and will grow higher post-Covid as people return to work. Q1 margin increased to 66%. EBITDA adjusted was $7 million vs. a $200 million loss last year. This equipment is offered in high-end spas like the Four Seasons. Costs only $200/facial, so anyone can afford it. However, SKIN isn't making money. They're seeing strong growth in Japan. This is a vanity play as we reopen and people want to meet other people. Good CEO who was the head of surgical for Baush.

The lack of profits in their track record worries him, but the strong upward movement of the chart tells him to give it the benefit of the doubt.

The CEO used to run Allergan. A fine CEO. He hasn't used SKIN's spa treatments, but he likes the stock.

It went public via SPAC earlier this year and one of the few successful SPACs because it boasts real profits and sales. They sell their Hydrafacial to health spas and dermatologists, then get a stream of recurring revenue each time a customer gets a $200 skin cleansing procedure. Up 40% since June when he recommended it.

It's terrific, though it should merge with Bausch. SKIN has a fabulous business open. When we get past Omicron, SKIN will really take off.

His dermatologist says that SKIN's product works well, but SKIN stock is a SPAC, because it's a SPAC, it goes down. If this had been a traditional IPO, shares would now be fine. But they sell a fine product and the company is run by a fresh CEO, so he wouldn't sell this.